The immune response in atherosclerosis: A double-edged sword

Nature Reviews Immunology

Volumn 6, Issue 7, 2006, Pages 508-519

  Hansson, Göran K ^a,b   Libby, Peter ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BETA2 GLYCOPROTEIN 1; HEAT SHOCK PROTEIN 65; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADAPTIVE BEHAVIOR; ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; IMMUNITY, NATURAL; MICE; MODELS, IMMUNOLOGICAL; PROGNOSIS; THROMBOSIS;

EID: 33745571976     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1882     Document Type: Review

References (133)

1. Murray, C. J. & Lopez, A. D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349, 1436-1442 (1997).
2. Jonasson, L., Holm, J., Skalli, O., Bondjers, G. & Hansson, G. K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6, 131-138 (1986).
3. Bobryshev, Y. V. & Lord, R. S. A. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovas. Res. 29, 689-696 (1995).
4. Kovanen, P. T., Kaartinen, M. & Paavonen, T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92, 1084-1088 (1995).
5. Jonasson, L., Holm, J., Skalli, O., Gabbiani, G. & Hansson, G. K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest 76, 125-131 (1985).
6. Plump, A. S. et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353 (1992).
7. Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M. & Maeda, N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl Acad. Sci. USA 89, 4471-4475 (1992).
8. Ishibashi, S., Goldstein, J. L., Brown, M. S., Herz, J. & Burns, D. K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93, 1885-1893 (1994).
9. Cybulsky, M. I. & Gimbrone, M. A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherosclerosis. Science 251, 788-791 (1991).
10. Nakashima, Y., Raines, E. W., Plump, A. S., Breslow, J. L. & Ross, R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18, 842-851 (1998).
11. Dai, G. et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and-resistant regions of human vasculature. Proc. Natl Acad. Sci. USA 101, 14871-14876 (2004).
12. Rajavashisth, T. B. et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344, 254-257 (1990).
13. Smith, J. D. et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl Acad. Sci. USA 92, 8264-8268 (1995).
14. Li, H., Cybulsky, M. I., Gimbrone, M. A. & Libby, P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am. J. Pathol. 143, 1551-1559 (1993).
15. Dong, Z. M. et al. The combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest. 102, 145-152 (1998).
16. Cybulsky, M. I. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107, 1255-1262 (2001).
17. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998).
18. Gu, L. et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2, 275-281 (1998).
19. Mach, F. et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104, 1041-1050 (1999).
20. Haley, K. J. et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102, 2185-2189 (2000).
21. Minami, M. et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21, 1796-1800 (2001).
22. Veillard, N. R. et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94, 253-261 (2004).
23. Combadiere, C. et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107, 1009-1016 (2003).
24. -/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111, 333-340 (2003).
25. Steinberg, D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272, 20963-20966 (1997).
26. Peiser, L., Mukhopadhyay, S. & Gordon, S. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14, 123-128 (2002).
27. Nicoletti, A. et al. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur. J. Immunol. 29, 512-521 (1999).
28. Moore, K. J. et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115, 2192-2201 (2005).
29. Bodzioch, M. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347-351 (1999).
30. Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
31. Edfeldt, K., Swedenborg, J., Hansson, G. K. & Yan, Z. Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161 (2002).
32. Kol, A., Lichtman, A. H., Finberg, R. W., Libby, P. & Kurt-Jones, E. A. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J. Immunol. 164, 13-17 (2000).
33. Xu, X. H. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104, 3103-3108 (2001).
34. Miller, Y. I. et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561-1568 (2003).
35. Michelsen, K. S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in a polipoprotein E. Proc. Natl Acad. Sci. USA 101, 10679-10684 (2004).
36. Bjorkbacka, H. et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Meet. 10, 416-421 (2004).
37. Paulsson, G., Zhou, X., Törnquist, E. & Hansson, G. K. Oligoclonal T cell expansions in atherosclerotic lesions of apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20, 10-17 (2000).
38. Stemme, S., Holm, J. & Hansson, G. K. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler. Thromb. 12, 206-211 (1992).
39. Angeli, V. et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21, 561-574 (2004).
40. Wang, X. et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nature Genet. 37, 365-372 (2005).
41. Swanberg, M. et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genet. 37, 486-494 (2005).
42. Stemme, S. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92, 3893-3897 (1995).
43. de Boer, O. J. et al. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc. Res. 48, 402-408 (2000).
44. Palinski, W. et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372-1376 (1989).
45. Palinski, W. et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest 98, 800-814 (1996).
46. Chicz, R. M. et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178, 27-47 (1993).
47. Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A. K. & Hansson, G. K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 108-114 (2001).
48. Stemme, S. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized LDL. Proc. Natl Acad. Sci. USA 92, 3893-3897 (1995).
49. Shaw, P. X. et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105, 1731-17340 (2000).
50. Binder, C. J. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nature Med. 9, 736-743 (2003).
51. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102, 2919-2922 (2000).
52. Tupin, E. et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199, 417-422 (2004).
53. Melian, A., Geng, Y. J., Sukhova, G. K., Libby, P. & Porcelli, S. A. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155, 775-786 (1999).
54. Nakai, Y. et al. Natural killer T cells accelerate atherogenesis in mice. Blood 104, 2051-2059 (2004).
55. Uyemura, K. et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest 97, 2130-2138 (1996).
56. Frostegard, J. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43. (1999).
57. Gupta, S. et al. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99, 2752-2761 (1997).
58. Buono, C. et al. Influence of interferon-γ on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 23, 454-460 (2003).
59. Davenport, P. & Tipping, P. G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117-1125 (2003).
60. Elhage, R. et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234-240 (2003).
61. Branen, L. et al. Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 24, 2137-2142 (2004).
62. Buono, C. et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl Acad. Sci. USA 102, 1596-1601 (2005).
63. -/- mice. Am. J. Pathol. 157, 1819-1824 (2000).
64. Laurat, E. et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104, 197-202 (2001).
65. Paigen, B., Morrow, A., Brandon, C., Mitchell, D. & Holmes, P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57, 65-73 (1985).
66. Huber, S. A., Sakkinen, P., David, C., Newell, M. K. & Tracy, R. P. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 103, 2610-2616 (2001).
67. Mallat, Z. et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89, E41-E45 (2001).
68. -/- mice through release of interferon-γ. Circ. Res. 90, e34-e38 (2002).
69. -/- mice. Arterioscler. Thromb. Vasc. Biol. 22, 456-461 (2002).
70. Shimizu, K., Shichiri, M., Libby, P., Lee, R. T. & Mitchell, R. N. Th2-predominant inflammation and blockade of IFN-γ signaling induce aneurysms in allografted aortas. J. Clin. Invest. 114, 300-308 (2004).
71. Friesel, R., Komoriya, A. & Maciag, T. Inhibition of endothelial cell proliferation by γ-interferon. J. Cell Biol. 104, 689-696 (1987).
72. Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L. & Gabbiani, G. Interferon γ inhibits both proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170, 1595-1608 (1989).
73. Amento, E. P., Ehsani, N., Palmer, H. & Libby, P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11, 1223-1230 (1991).
74. van Hinsbergh, V. W. M., van den Berg, E. A., Fiers, W. & Dooijewaard, G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75, 1991-1998 (1990).
75. Lee, E. et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ. Res. 78, 44-49 (1996).
76. Saren, P., Welgus, H. G. & Kovanen, P. T. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157, 4159-4165 (1996).
77. Jovinge, S. et al. Evidence for a role of tumor necrosis factor α in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 47, 113-118 (1998).
78. Boquist, S. et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 100, 723-728 (1999).
79. Beutler, B. & Cerami, A. Cachectin and tumour necrosis factor as two sided of the same biological coin. Nature 320, 584-588 (1986).
80. Mach, F., Schoenbeck, U., Bonnefoy, J.-Y., Pober, J. & Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation 96, 396-399 (1997).
81. Mach, F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages- implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl Acad. Sci. USA 94, 1931-1936 (1997).
82. Henn, V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
83. Mach, F., Schönbeck, U., Sukhova, G. K., Atkinson, E. & Libby, P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200-203 (1998).
84. Lutgens, E. et al. Requirement for CD154 in the progression of atherosclerosis. Nature Med. 5, 1313-1316 (1999).
85. Mallat, Z. et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17-e24 (1999).
86. Pinderski Oslund, L. J. et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 2847-53 (1999).
87. Caligiuri, G. et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9, 10-17 (2003).
88. Grainger, D. J. et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med. 1, 74-79 (1995).
89. Mallat, Z. et al. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-934 (2001).
90. Lutgens, E. et al. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22, 975-982 (2002).
91. Robertson, A. K. et al. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350 (2003).
92. Gojova, A. et al. Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102, 4052-4058 (2003).
93. Ait-Oufella, H. et al., Natural regulatory T cells control the development of atherosclerosis in mice. Nature Med. 12, 178-180 (2006).
94. Salonen, J. T. et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883-887 (1992).
95. Fredrikson, G. N. et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23, 872-878 (2003).
96. Shaw, P. X. et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions In vivo. Arterioscler. Thromb. Vasc. Biol. 21, 1333-1339 (2001).
97. Kol, A., Sukhova, G. K., Lichtman, A. H. & Libby, P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 98, 300-307 (1998).
98. Xu, Q. et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341, 255-259 (1993).
99. Perschinka, H. et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 1060-1065 (2003).
100. Caligiuri, G., Nicoletti, A., Poirier, B. & Hansson, G. K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109, 745-753 (2002).
101. Libby, P. & Aikawa, M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nature Med. 8, 1257-1262 (2002).
102. Henney, A. M. et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl Acad. Sci. USA 88, 8154-8158 (1991).
103. Galis, Z. S., Sukhova, G. K., Lark, M. W. & Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnarable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503 (1994).
104. Dollery, C. & Libby, P. Atherosclerosis and proteinase activation. Cardiovasc. Res. 69, 625-635 (2006).
105. + T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J. Pathol. 201, 288-295 (2003).
106. Poon, M., Badimon, J. J. & Fuster, V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 359, 619-622 (2002).
107. Jonasson, L., Holm, J. & Hansson, G. K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl Acad. Sci. USA 85, 2303-2306 (1988).
108. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
109. Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
110. Greenwood, J., Steinman, L. & Zamvil, S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nature Rev. Immunol. 6, 358-370
111. Takemoto, M. & Liao, J. K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21, 1712-1719 (2001).
112. Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nature Med. 6, 1399-1402 (2000).
113. Mehra, M. R. & Raval, N. Y. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant. Proc. 36, 1539-1541 (2004).
114. McCarey, D. W. et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004).
115. Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
116. Marx, N. et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90, 703-710 (2002).
117. Staels, B. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793 (1998).
118. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
119. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
120. Mattner, J. et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434, 525-529 (2005).
121. Liuzzo, G. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 417-424 (1994).
122. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
123. Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
124. Palinski, W., Miller, E. & Witztum, J. L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821-825 (1995).
125. Ameli, S. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16, 1074-1079 (1996).
126. George, J. et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147-152 (1998).
127. Freigang, S., Hörkkö, S., Miller, E., Witztum, J. L. & Palinski, W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18, 1972-1982 (1998).
128. Fredrikson, G. N. et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler. Thromb. Vasc. Biol. 23, 879-884 (2003).
129. + T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 864-870 (2006).
130. Afek, A. et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14, 115-121 (2000).
131. Harats, D., Yacov, N., Gilburd, B., Shoenfeld, Y. & George, J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J. Am. Coll. Cardiol. 40, 1333-1338 (2002).
132. Maron, R. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106, 1708-1715 (2002).
133. George, J. et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation 98, 1108-1115 (1998).